Veterinary Medicines

Amoxibactin 250 mg tablets for dogs

Authorised
  • Amoxicillin trihydrate
Download as PDF

Product identification

Medicine name:
Amoxibactin 250 mg tablets for dogs
Amoxibactin 250 mg Tablet
Amoxibactin 250 mg Comprimé
Amoxibactin 250 mg Tablette
Active substance:
  • Amoxicillin trihydrate
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Amoxicillin trihydrate
    287.50
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01CA04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Cardboard box of 9 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
  • Cardboard box of 8 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
  • Cardboard box of 7 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
  • Cardboard box of 6 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
  • Cardboard box of 3 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
  • Cardboard box of 25 Aluminium - PVC/PE/PVDC blisters of 10 tablets
  • Cardboard box of 2 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
  • Cardboard box of 10 Aluminium - PVC/PE/PVDC blisters of 10 tablets
  • Cardboard box of 1 Aluminium - PVC/PE/PVDC blister of 10 tablets.
  • Cardboard box of 50 Aluminium - PVC/PE/PVDC blisters of 10 tablets
  • Cardboard box of 5 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
  • Cardboard box of 4 Aluminium - PVC/PE/PVDC blisters of 10 tablets.
  • Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Le Vet. Beheer B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V483697
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0186/002
Concerned member states:
  • Austria
  • Belgium
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Slovakia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download
German (PDF)
Published on: 22/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."